Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Jacobsohn, David  [Clear All Filters]
Journal Article
Rossoff J, Jacobsohn D, Kwon S, Kletzel M, Duerst RE, Tse WT, Schneiderman J, Chaudhury S. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatr Blood Cancer. 2021:e29087.
Dowlut-McElroy T, Shin S, Stepanek E, Jacobsohn D, Gomez-Lobo V. Pediatric vulvovaginal graft-versus-host disease: A retrospective cohort study and literature review. J Pediatr Adolesc Gynecol. 2022.
Hanisch BR, Cohen W, Jacobsohn D, Song X. Impact of Hospital Acquired Infections on Post-Transplant One Year Mortality in Pediatric Bone Marrow Transplant Patients. Am J Infect Control. 2020.
Bhatt ST, Bednarski JJ, Berg J, Trinkaus K, Murray L, Hayashi R, Schulz G, Hente M, Grimley M, Chan KWah, et al. Immune Reconstitution and Infection Patterns Following Early Alemtuzumab and Reduced Intensity Transplantation for Non-Malignant Disorders in Pediatric Patients. Biol Blood Marrow Transplant. 2018.
Shah NC, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier GDE, Godder K, Grimley M, et al. Granulocyte Colony-Stimulating Factor is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplant Cell Ther. 2021.
Takahashi T, Watkins B, Bratrude B, Neuberg D, Hebert K, Betz K, Yu A, Choi SW, Davis J, Duncan C, et al. The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplant Cell Ther. 2024.
Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020;4(16):3894-3899.